137 related articles for article (PubMed ID: 32389031)
41. Albumin-to-fibrinogen ratio is an independent prognostic parameter in de novo non-M3 acute myeloid leukemia.
Ding Y; Qi X; Li Y; Sun Y; Wan J; Luo C; Huang Y; Li Q; Wu G; Zhu X; Xu S
Clin Exp Med; 2023 Dec; 23(8):4597-4608. PubMed ID: 37914966
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level.
Lee YY; Choi CH; Sung CO; Do IG; Huh S; Song T; Kim MK; Kim HJ; Kim TJ; Lee JW; Kim BG; Bae DS
Gynecol Oncol; 2012 Jan; 124(1):92-7. PubMed ID: 22014631
[TBL] [Abstract][Full Text] [Related]
43. SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer.
van de Lande J; Davelaar EM; von Mensdorff-Pouilly S; Water TJ; Berkhof J; van Baal WM; Kenemans P; Verheijen RH
Gynecol Oncol; 2009 Jan; 112(1):119-25. PubMed ID: 19007978
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.
Lubowicka E; Zbucka-Kretowska M; Sidorkiewicz I; Zajkowska M; Gacuta E; Puchnarewicz A; Chrostek L; Szmitkowski M; Ławicki S
Pathol Oncol Res; 2020 Apr; 26(2):791-800. PubMed ID: 30820752
[TBL] [Abstract][Full Text] [Related]
45. The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer.
Pan L; Cheng J; Zhou M; Yao Z; Zhang Y
J Cancer Res Clin Oncol; 2012 Feb; 138(2):239-46. PubMed ID: 22102174
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
[TBL] [Abstract][Full Text] [Related]
47. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
48. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer.
Chen W; Xiu S; Xie X; Guo H; Xu Y; Bai P; Xia X
Radiat Oncol; 2022 Jan; 17(1):6. PubMed ID: 35012582
[TBL] [Abstract][Full Text] [Related]
50. The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapy.
Yoon SM; Shin KH; Kim JY; Seo SS; Park SY; Kang S; Cho KH
Int J Gynecol Cancer; 2007; 17(4):872-8. PubMed ID: 17343571
[TBL] [Abstract][Full Text] [Related]
51. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
52. CTHRC1 as a novel biomarker in the diagnosis of cervical squamous cell carcinoma.
Xu G; Fan W; Wang F; Lu H; Xing X; Zhang R; Jiang P
Int J Clin Exp Pathol; 2018; 11(2):847-854. PubMed ID: 31938174
[TBL] [Abstract][Full Text] [Related]
53. Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence.
Salvatici M; Achilarre MT; Sandri MT; Boveri S; Vanna Z; Landoni F
Gynecol Oncol; 2016 Jul; 142(1):115-119. PubMed ID: 27117922
[TBL] [Abstract][Full Text] [Related]
54. Serum YKL-40 as a marker for cervical adenocarcinoma.
Mitsuhashi A; Matsui H; Usui H; Nagai Y; Tate S; Unno Y; Hirashiki K; Seki K; Shozu M
Ann Oncol; 2009 Jan; 20(1):71-7. PubMed ID: 18723551
[TBL] [Abstract][Full Text] [Related]
55. The curative role of radiotherapy in patients with isolated para-aortic node recurrence from cervical cancer and value of squamous cell carcinoma antigen for early detection.
Ogino I; Nakayama H; Kitamura T; Okamoto N; Inoue T
Int J Gynecol Cancer; 2005; 15(4):630-8. PubMed ID: 16014117
[TBL] [Abstract][Full Text] [Related]
56. The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix.
Nakamura K; Okumura Y; Kodama J; Hongo A; Kanazawa S; Hiramatsu Y
Gynecol Oncol; 2010 Oct; 119(1):81-6. PubMed ID: 20580064
[TBL] [Abstract][Full Text] [Related]
57. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases.
Piao X; Kong TW; Chang SJ; Paek J; Chun M; Ryu HS
Gynecol Oncol; 2015 Jul; 138(1):89-93. PubMed ID: 25913134
[TBL] [Abstract][Full Text] [Related]
58. Can serial evaluation of serum SCC-Ag-level predict tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix treated with definitive chemoradiotherapy? A multi-institutional analysis.
Choi KH; Yu M; Jeong S; Lee JH
Int J Clin Oncol; 2020 Jul; 25(7):1405-1411. PubMed ID: 32221801
[TBL] [Abstract][Full Text] [Related]
59. Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy.
Wang W; Liu X; Hou X; Lian X; Liu Z; Shen J; Sun S; Yan J; Miao Z; Wang D; Meng Q; Fu J; Zhang F; Qiu J; Hu K
Gynecol Oncol; 2019 Nov; 155(2):224-228. PubMed ID: 31500891
[TBL] [Abstract][Full Text] [Related]
60. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
Ying J; Zhou D; Gu T; Huang J; Liu H
BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
